vasobral has been researched along with caffeine in 9 studies
*Caffeine: A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. [MeSH]
*Caffeine: A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. [MeSH]
| Studies (vasobral) | Trials (vasobral) | Recent Studies (post-2010) (vasobral) | Studies (caffeine) | Trials (caffeine) | Recent Studies (post-2010) (caffeine) |
|---|---|---|---|---|---|
| 10 | 2 | 3 | 25,501 | 2,393 | 6,825 |
| Protein | Taxonomy | vasobral (IC50) | caffeine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 7.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Migeon, P; Poncin-Lafitte, M; Rancurel, G; Rapin, JR | 1 |
| Burdukovskaia, NL; Molokov, DD; Shprakh, VV; Tatarinova, MB | 1 |
| Sadekov, RA | 1 |
| Grinshteĭn, AB; Kromm, OK; Pavlovskaia, MV; Shnaĭder, NA | 1 |
| Zaĭtseva, IN | 1 |
| Azimova, IuE; Tabeeva, GR | 1 |
| Kamchatnov, PR | 2 |
| Barantsevich, ER; Belskaya, GN; Kopishinskaya, SV; Levin, OS; Lukashevich, IG; Ostroumova, OD; Psokhina, OV; Radiuk, MA; Vasenina, EE | 1 |
2 trial(s) available for vasobral and caffeine
| Article | Year |
|---|---|
[The use of vasobral in patients with chronic cerebrovascular disorders].
Topics: Adult; Aged; Caffeine; Cerebrovascular Disorders; Chronic Disease; Dihydroergotoxine; Drug Combinations; Female; Humans; Male; Middle Aged; Treatment Outcome | 2011 |
[Efficacy of the combination drug vasobral in chronic vascular encephalopathy].
Topics: Adult; Aged; Brain Damage, Chronic; Brain Ischemia; Caffeine; Cerebral Small Vessel Diseases; Dihydroergotoxine; Drug Combinations; Female; Humans; Male; Middle Aged; Treatment Outcome | 2014 |
7 other study(ies) available for vasobral and caffeine
| Article | Year |
|---|---|
[Vasobral and stabilized cerebral vascular complication: hemodynamic and psychometric study].
Topics: Aged; Brain Ischemia; Caffeine; Cerebrovascular Circulation; Dihydroergotoxine; Drug Combinations; Humans; Middle Aged; Psychometrics | 1987 |
[Vasobral in the treatment of initial atherosclerotic circulatory encephalopathy].
Topics: Adult; Aged; Caffeine; Dihydroergotoxine; Drug Combinations; Drug Evaluation; Female; Humans; Intracranial Arteriosclerosis; Male; Middle Aged | 1996 |
[The influence of alpha-dihydroergocryptine derivatives on psychomotor manifestations in Parkinson disease].
Topics: Antiparkinson Agents; Caffeine; Dihydroergotoxine; Drug Combinations; Female; Humans; Male; Memory; Middle Aged; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 2000 |
[Experience in the administration of vasobral in sensorineural vascular hypoasusis].
Topics: Administration, Oral; Adult; Caffeine; Dihydroergotoxine; Drug Administration Schedule; Drug Combinations; Hearing Loss, Sensorineural; Humans; Neuroprotective Agents; Osteochondritis; Retrospective Studies; Vertebrobasilar Insufficiency | 2001 |
[Use of vasobral in therapy of central nervous system pathology in children of early age].
Topics: Administration, Oral; Caffeine; Central Nervous System Diseases; Child, Preschool; Dihydroergotoxine; Dose-Response Relationship, Drug; Drug Combinations; Follow-Up Studies; Humans; Infant; Psychomotor Performance; Treatment Outcome | 2010 |
[Preventive treatment of migraine with vasobral: a multicenter trial].
Topics: Adolescent; Adult; Aged; Caffeine; Dihydroergotoxine; Drug Combinations; Female; Humans; Male; Middle Aged; Migraine Disorders; Prospective Studies; Treatment Outcome; Young Adult | 2010 |
[Vasobral in the treatment of brain lesions: views of physicians and patients].
Topics: Caffeine; Cerebrovascular Disorders; Cognition; Cognition Disorders; Dihydroergotoxine; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Memory; Patients; Physicians; Surveys and Questionnaires; Vertigo | 2013 |